Novo corrals 3 new early-stage obesity drugs from Kallyope
Novo has brought in three early-stage obesity drug candidates from Kallyope.
Kallyope
Private
Clinical-stage biotech leveraging insights into neural signaling pathways to develop novel medicines for migraine and metabolic disorders, with a late-stage pipeline built on newly identified neural circuits.
Company Info
Sector:Biotechnology / Small Molecule Pharma
Headquarters:New York, New York, USA
Founded:2015
Website:kallyope.com/